{"id":3058,"date":"2017-09-26T16:49:10","date_gmt":"2017-09-26T20:49:10","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3058"},"modified":"2017-09-26T16:49:17","modified_gmt":"2017-09-26T20:49:17","slug":"secondaries-announced-9-26-17","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/secondaries-announced-9-26-17\/","title":{"rendered":"Secondaries Announced 9.26.17"},"content":{"rendered":"

IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis.<\/strong><\/h4>\n

If having\u00a0real-time alerts for secondary offerings<\/strong><\/a>\u00a0would be an advantage to you,\u00a0inquire about a subscription today!<\/a><\/p>\n

Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or opening trade) time period.<\/p>\n

Company: Intra-Cellular Therapies Inc.<\/strong>
\nSymbol: ITCI
\nPrice: Last Trade $19.23
\nTrade Date: 9\/28
\nShares: 7.8 million ($150 million cash raise)
\nUnderwriter(s) : J. P. Morgan Securities, Leerink Partners
\nDescription: Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson\u2019s and Alzheimer\u2019s disease.
\nRating = Subscription Needed<\/a><\/p>\n

Company: Westlake Chemical Partners<\/strong>
\nSymbol: WLKP
\nPrice: Last Trade $24.10
\nTrade Date: 9\/27
\nShares: 4.5 million
\nRe-Offer Range: Subscription Needed<\/a>
\nUnderwriter(s) : UBS Investment Bank, Citigroup, Barclays, BofA Merrill Lynch
\nDescription: Westlake Chemical Partners is a limited partnership formed by Westlake Chemical Corporation to operate, acquire and develop ethylene production facilities and other qualified assets.
\nRating = Subscription Needed<\/a><\/p>\n

Company: Ascendis Pharma<\/strong>
\nSymbol: ASND
\nPrice: Last Trade $37.10
\nTrade Date: 9\/27
\nRe-Offer Range:Subscription Needed<\/a>
\nShares: 3.4 million ($125m cash raise)
\nUnderwriter(s) : J.P. Morgan, BofA Merrill Lynch, Credit Suisse Securities
\nDescription: Ascendis Pharma is a biopharmaceutical company applying its TransCon technology to develop a pipeline of sustained release prodrug therapies with best-in-class profiles to address significant unmet medical needs in rare diseases.
\nRating = Subscription Needed<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis. If having\u00a0real-time alerts for secondary offerings\u00a0would be an advantage to you,\u00a0inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[35],"tags":[25,179,1360],"class_list":["post-3058","post","type-post","status-publish","format-standard","hentry","category-secondary-offerings","tag-asnd","tag-itci","tag-wlkp"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3058"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3058\/revisions"}],"predecessor-version":[{"id":3059,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3058\/revisions\/3059"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}